Dosing and Reasons for Transitioning From Sodium Oxybate to Lower-Sodium Oxybate: Data From the Transition Experience of Patients With Narcolepsy Taking Oxybate in the Real-World (TENOR) Study

Abstract: Introduction: The TENOR study examines the impact of transitioning from sodium oxybate (SXB) to lower-sodium oxybate (LXB; 92% less sodium than SXB) in a real-world setting. Methods: TENOR is a patient-centric, prospective, observational, noninterventional, virtual-format study (NCT04803786). Eligible participants include US adults with narcolepsy (type 1 or 2) transitioning from SXB to LXB within the previous/upcoming 7 days. Data are collected for 21 weeks post-transition. Analyses include data collected at initiation of LXB treatment from qualifying participants. Results: Analyses included 85 participants with narcolepsy (type 1, n=45; type 2, n=40). Mean (SD) age was 40.3 (13.0) years; most participants were female (73%), White (87%), and took ≥1 concomitant medication for narcolepsy at baseline with SXB (79% [38% taking 1, 33% taking 2, and 8% taking ≥3]). Mean (SD) time on current SXB regimen was 57.8 (52.1) months. Most (96%) participants took SXB twice nightly. After transitioning, 98% of participants took LXB twice nightly. SXB-to-LXB dose conversions at baseline were gram-for-gram in most (87%) participants. Fifty-six percent of participants were taking a total LXB dose >7.5 g/night. Participant-reported reasons for transitioning to LXB (multiple selections allowed) included lower sodium content for improved long-term health (93%), physician recommendation (47%), to avoid cardiovascular issues (39%), to avoid side effects (31%), to improve narcolepsy symptom control (18%), and other (14%). Conclusions: Most participants transitioned from SXB to LXB using a gram-for-gram dose conversion. The most common reason for switching was for improved long-term health due to the lower sodium content of LXB.Short Description: These analyses describe characteristics and dosing strategies of participants in the Transition Experience of Patients With Narcolepsy Taking Oxybate in the Real-World (TENOR) study. The findings provide valuable insights regarding the transition from sodium oxybate (SXB) to lower-sodium oxybate (LXB) in a real-world setting. Most participants transitioned gram-for-gram from SXB to LXB and for improved long-term health reasons (due to lower sodium content). The transition was prompted by physicians and participants at a similar rate.Name of Sponsoring Organization(s): Jazz Pharmaceuticals